Press

High-Tech Gründerfonds and Bayern Kapital invest in Lophius Biosciences

October 2, 2008

Regensburg-based biotech company to receive 600,000 euros venture capital for the development of novel diagnostic tools to detect infectious and autoimmune diseases

Lophius Biosciences GmbH (Regensburg) has successfully closed its first financing round. High-Tech Gründerfonds (Bonn, Germany) and Bayern Kapital (Landshut, Germany) invest a total 600,000 euros in the young Biotech company. The funding will be used for the development of novel diagnostic tools for rising diseases such as tuberculosis, the world‘s greatest infectious killer of women of reproductive age and the leading cause of death among people with HIV/AIDS.
Lophius Bioscience is accompanied by netzwerk|nordbayern since its participation to the Nordbayern Business Plan Competition (BPWN) in 2006.

Proprietary technology
Lophius Biosciences owns a unique and patented technology, named Reverse T-cell Technology (RTT) for the fast and reliable detection of activated T helper cells and its target structures. T helper cells play a crucial role in the control of acute microbial infections and the onset of autoimmune diseases. Using RTT will allow for the first time an accurate discrimination between active and latent tuberculosis infections. Furthermore, RTT-based diagnostics are under development to identify the beginning of autoimmune diseases even before clinical symptoms become manifest. Consequently, an early diagnosis is of major importance to prevent and to selectively treat autoimmune diseases.

Growth potential
With its proprietary RT-technology, Lophius Biosciences has excellent growth opportunities. Already today, Lophius Biosciences is developing tailor made cell-based bioassays e.g. to test the biological activity and quality of protein-based therapeutics and vaccines in charge of international pharmaceutical partners. With the growing amount of registered biopharmaceuticals on the market, specialized contract research gains more and more importance.

About Lophius Biosciences:
Lophius Biosciences GmbH is a spin-off of the Institute for Medicinal Microbiology and Hygiene and the Department of Internal Medicine I at the University Hospital of Regensburg located in Regensburg, the south-east of Germany. The young biotechnology company offers services to assess the safety, quality and efficacy of biological agents.

The company’s service portfolio includes:
• Determination of toxicity and immunomodulatory properties of test substances in cell cultures and in animal models.
• Development and qualification of cell based assays to control biological activity and safety of protein based drugs and vaccines.
• Detection und quantification of specific antibodies as well as T-cells mapping of B- and T-cell epitopes.
• Evaluation of the immunogenicity of active ingredients in animal models.

In addition, Lophius Biosciences is developing innovative technologies for the diagnosis of acute infectious and autoimmune diseases as well as the rapid and efficient identification of novel T-cell epitopes (epitope database).

Contact:
Lophius Biosciences GmbH
Ludwig Deml, PD Dr.
Josef-Engert-Straße 9
D-93053 Regensburg
Germany
Tel: +49 941 944-4637
Fax: +49 721 151 397 812
info@lophius-biosciences.de
www.lophius-biosciences.de

About High-Tech Gründerfonds:
The High-Tech Gründerfonds invests venture capital in young technology companies that transform promising scientific research into business enterprises. The seed financing of up to 500 T€ shall result in a technical prototype, a proof of concept or a proof of market. High-Tech Gründerfonds has access to a fund volume of around 272,0 million Euro. Investors in this public-private partnership include the Federal Ministry for Economy and Technology, the KfW Banking Group as well as the six industry companies BASF, Robert Bosch, Carl Zeiss, Daimler, Deutsche Telekom and Siemens.

Contact:
High-Tech Gründerfonds Management GmbH
Ludwig-Erhard-Allee 2
53175 Bonn
Tel: +49 228 – 965685-00
Fax: +49 228 – 965685-50
info@high-tech-gruenderfonds.de
www.high-tech-gruenderfonds.de

About:
The Seedfonds Bayern was started in 2003. With a fund size of 22 million Euro it is focused on investments in early stage technology companies in Bavaria. The fund is managed by Bayern Kapital which was founded in 1995 by the Bavarian Government as part of the campaign “Initiative Bavarian Future” and to provide young and innovated Bavarian companies with venture capital. Up to date Bayern Kapital has invested in over 165 innovative high-tech companies with a total investment volume of about 135 million Euro. Overall, Bayern Kapital now manages a fund volume of almost 190 million Euro and implement the Clusterfonds Bayern concept with a fund volume von furthermore 75 million Euro. Seedfonds Bayern managed by Bayern Kapital:

Contact:
Bayern Kapital GmbH
Ländgasse 135a
84028 Landshut
Tel: +49-871-923 25 0
info@bayernkapital.de
www.bayernkapital.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc